The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, raised $27 million by offering 2.7 million shares at $10, the low end of the range of $10 to $12. The company offered 0.4 million more shares than anticipated. At pricing,...read more
Updated Monday, 2/8. The IPO market is buzzing with 15 IPOs slated to raise $4.0 billion in the week ahead, led by dating app Bumble’s billion-dollar offering. Bumble (BMBL) plans to raise $1.7 billion at a $7.5...read more
Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, announced terms for its IPO on Wednesday. The Miami, FL-based company plans to raise $25 million by offering 2.3 million shares at a price range of $10 to $12. At the...read more
US IPO Weekly Recap: IPO frenzy brings the year’s largest deal and biggest pop in a 17 IPO week
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Cell therapy biotech Longeveron prices IPO at $10 low end
Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, raised $27 million by offering 2.7 million shares at $10, the low end of the range of $10 to $12. The company offered 0.4 million more shares than anticipated. At pricing,...read more
US IPO Week Ahead: Bumble’s billion-dollar deal leads a buzzy 15 IPO week
Updated Monday, 2/8. The IPO market is buzzing with 15 IPOs slated to raise $4.0 billion in the week ahead, led by dating app Bumble’s billion-dollar offering. Bumble (BMBL) plans to raise $1.7 billion at a $7.5...read more
Cell therapy biotech Longeveron sets terms for $25 million IPO
Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, announced terms for its IPO on Wednesday. The Miami, FL-based company plans to raise $25 million by offering 2.3 million shares at a price range of $10 to $12. At the...read more